MX2022015254A - N-cianopirrolidinas con actividad como inhibidores de peptidasa especifica de ubiquitina 30. - Google Patents

N-cianopirrolidinas con actividad como inhibidores de peptidasa especifica de ubiquitina 30.

Info

Publication number
MX2022015254A
MX2022015254A MX2022015254A MX2022015254A MX2022015254A MX 2022015254 A MX2022015254 A MX 2022015254A MX 2022015254 A MX2022015254 A MX 2022015254A MX 2022015254 A MX2022015254 A MX 2022015254A MX 2022015254 A MX2022015254 A MX 2022015254A
Authority
MX
Mexico
Prior art keywords
cyanopyrrolidines
activity
inhibitors
usp30
usp30 inhibitors
Prior art date
Application number
MX2022015254A
Other languages
English (en)
Inventor
Mark Ian Kemp
Paul William Thompson
Christopher Andrew Luckhurst
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2008401.8A external-priority patent/GB202008401D0/en
Priority claimed from GBGB2016689.8A external-priority patent/GB202016689D0/en
Priority claimed from GBGB2101935.1A external-priority patent/GB202101935D0/en
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Publication of MX2022015254A publication Critical patent/MX2022015254A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se refiere a una clase de N-cianopirrolidinas con actividad como inhibidores de la enzima de desubiquitinación USP30, que tiene utilidad en una variedad de áreas terapéuticas, incluyendo condiciones que involucran la disfunción mitocondrial, cáncer y fibrosis: (ver Fórmulas).
MX2022015254A 2020-06-04 2021-06-03 N-cianopirrolidinas con actividad como inhibidores de peptidasa especifica de ubiquitina 30. MX2022015254A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2008401.8A GB202008401D0 (en) 2020-06-04 2020-06-04 Novel compounds
GBGB2016689.8A GB202016689D0 (en) 2020-10-21 2020-10-21 Novel compounds
GBGB2101935.1A GB202101935D0 (en) 2021-02-11 2021-02-11 Novel compounds
PCT/EP2021/064897 WO2021245186A1 (en) 2020-06-04 2021-06-03 N-cyanopyrrolidines with activity as usp30 inhibitors

Publications (1)

Publication Number Publication Date
MX2022015254A true MX2022015254A (es) 2023-01-11

Family

ID=76421953

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015254A MX2022015254A (es) 2020-06-04 2021-06-03 N-cianopirrolidinas con actividad como inhibidores de peptidasa especifica de ubiquitina 30.

Country Status (12)

Country Link
US (1) US20230303547A1 (es)
EP (1) EP4161920A1 (es)
JP (1) JP2023529570A (es)
KR (1) KR20230019198A (es)
CN (1) CN115698001A (es)
AU (1) AU2021285130A1 (es)
BR (1) BR112022019722A2 (es)
CA (1) CA3185654A1 (es)
CO (1) CO2022017112A2 (es)
IL (1) IL298710A (es)
MX (1) MX2022015254A (es)
WO (1) WO2021245186A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023099561A1 (en) 2021-12-01 2023-06-08 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2001077073A1 (en) 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
BRPI0709950A2 (pt) 2006-04-13 2011-08-02 Actelion Pharmaceuticals Ltd uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
TW200922556A (en) 2007-08-20 2009-06-01 Glaxo Group Ltd Novel cathepsin C inhibitors and their use
AR071369A1 (es) 2008-04-18 2010-06-16 Glaxo Group Ltd Compuesto de 1- ciano-3-pirrolidinil-n-sustituido-sulfonamida, su uso para preparar un medicamento util para tratar una enfermedad pulmonar obstructiva cronica y composicion farmaceutica que lo comprende
AR071480A1 (es) 2008-04-18 2010-06-23 Glaxo Group Ltd Compuesto de 1- ciano -3- pirrolidinil -bencenosulfonamida composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar la enfermedad pulmonar obstructiva cronica (copd )
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
US20120309820A1 (en) 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
LT3049417T (lt) 2013-07-31 2019-02-11 Merck Patent Gmbh Piridinai, pirimidnai ir pirazinai kaip btk inhibitoriai ir jų panaudojimas
US9963444B2 (en) 2014-05-19 2018-05-08 Northeastern University N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof
US20170095457A1 (en) 2014-05-27 2017-04-06 David Lonergan Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
WO2016156816A1 (en) 2015-03-30 2016-10-06 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors
EP3800186A1 (en) 2015-07-14 2021-04-07 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
EP3433246B1 (en) 2016-03-24 2022-05-04 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as dbu inhibitors
WO2018060689A1 (en) 2016-09-27 2018-04-05 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of usp30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
US10968172B2 (en) 2017-05-15 2021-04-06 Mitobridge, Inc. USP30 inhibitors
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
GB2563595B (en) 2017-06-19 2020-04-15 Edwards Ltd Twin-shaft pumps
CN111148743B (zh) 2017-10-06 2023-12-15 福马治疗有限公司 抑制泛素特异性肽酶30
GB2571731A (en) 2018-03-06 2019-09-11 Mission Therapeutics Ltd Novel compounds and uses
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
EP3837262A1 (en) 2018-08-14 2021-06-23 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
CA3110113A1 (en) 2018-10-05 2020-04-09 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
EP4161920A1 (en) 2023-04-12
IL298710A (en) 2023-02-01
JP2023529570A (ja) 2023-07-11
US20230303547A1 (en) 2023-09-28
KR20230019198A (ko) 2023-02-07
WO2021245186A1 (en) 2021-12-09
AU2021285130A1 (en) 2023-01-19
CO2022017112A2 (es) 2022-12-09
BR112022019722A2 (pt) 2022-12-20
CN115698001A (zh) 2023-02-03
CA3185654A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
ZA202203775B (en) Substituted cyanopyrrolidines with activity as usp30 inhibitors
MX2022012578A (es) N-cianopirrolidinas con actividad como inhibidores de usp30.
CO2022017233A2 (es) 1-(5-(2-cianopiridin-4-il)oxazol-2-carbonil)-4-metilhexahidropirrolo[3,4-b]pirrol-5(1h)-carbonitrilo como inhibidor de usp30 para uso en el tratamiento de la disfunción mitocondrial, cáncer y fibrosis
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MX2023000998A (es) Composiciones genomodificadas dirigidas a los musculos.
MX2016006489A (es) Alfa-amilasas variantes que tienen susceptibilidad reducida a la escision por proteasas y metodos de uso.
UY27921A1 (es) Acidos tienil-hidroxamicos sustituidos y su uso para tratar enfermedades asociadas con la actividad enzimática de la histona desacetilasa
MX2022007376A (es) Fluoroalqull-oxadiazoles y sus usos.
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
MX2022015254A (es) N-cianopirrolidinas con actividad como inhibidores de peptidasa especifica de ubiquitina 30.
NZ589191A (en) Quinazoline derivatives that inhibit the activity of egfr
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
PH12020551555A1 (en) Calpain modulators and therapeutic uses thereof
WO2023081830A3 (en) Compositions and treatments with nirogacestat
MX2022014429A (es) N-cianopirrolidinas con actividad como inhibidores de usp30.
WO2022192487A3 (en) Methyl-substituted pyridine and pyridazine compounds, derivatives thereof, and methods of their use
MX2023007080A (es) Metodo para el tratamiento de la fibrosis.
WO2019204332A3 (en) Pak4 inhibitors and methods of use
MX2023002416A (es) Compuestos, composiciones y metodos para la inhibicion de la desmetilasa de histona lisina.
WO2023019100A3 (en) Novel therapeutic methods of using peptidoglycan muropeptides to promote atp synthase activity and mitochondrial homeostasis and development
CR20220588A (es) Formulaciones farmacéuticas de acetato de abiraterona y niraparib
WO2020222241A8 (en) Compositions comprising the propeptide of lysyl oxidase and uses thereof
WO2023056365A3 (en) Irhom2 inhibitors and uses thereof
MX2022014239A (es) Nuevos agonistas de il10 y metodos para su uso.
PL414890A1 (pl) Środek aktywujący